Literature DB >> 20433840

Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease.

Mark J Asquith1, Olivier Boulard, Fiona Powrie, Kevin J Maloy.   

Abstract

BACKGROUND & AIMS: Toll-like receptors (TLR) are innate immune receptors involved in recognition of the intestinal microflora; they are expressed by numerous cell types in the intestine, including epithelial cells, myeloid cells, and lymphocytes. Little is known about the relative contributions of TLR signaling in distinct cellular compartments to intestinal homeostasis. We aimed to define the roles of TLR signals in distinct cell types in the induction and regulation of chronic intestinal inflammation.
METHODS: We assessed the roles of the shared TLR signaling adaptor protein, MyD88, in several complementary mouse models of inflammatory bowel disease, mediated by either innate or adaptive immune activation. MyD88-deficient mice and bone marrow chimeras were used to disrupt TLR signals selectively in distinct cellular compartments in the intestine.
RESULTS: MyD88-dependent activation of myeloid cells was required for the development of chronic intestinal inflammation. By contrast, although epithelial cell MyD88 signals were required for host survival, they were insufficient to induce intestinal inflammation in the absence of an MyD88-competent myeloid compartment. MyD88 expression by T cells was not required for their pathogenic and regulatory functions in the intestine.
CONCLUSIONS: Cellular compartmentalization of MyD88 signals in the intestine allow the maintenance of host defense and prevent deleterious inflammatory responses. Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433840      PMCID: PMC3739016          DOI: 10.1053/j.gastro.2010.04.045

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  41 in total

1.  Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains.

Authors:  P Markel; P Shu; C Ebeling; G A Carlson; D L Nagle; J S Smutko; K J Moore
Journal:  Nat Genet       Date:  1997-11       Impact factor: 38.330

2.  Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

Authors:  Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

3.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

4.  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Authors:  Guangyong Peng; Zhong Guo; Yukiko Kiniwa; Kui Shin Voo; Weiyi Peng; Tihui Fu; Daniel Y Wang; Yanchun Li; Helen Y Wang; Rong-Fu Wang
Journal:  Science       Date:  2005-08-26       Impact factor: 47.728

5.  Opposing functions of IKKbeta during acute and chronic intestinal inflammation.

Authors:  Lars Eckmann; Tim Nebelsiek; Alexander A Fingerle; Sara M Dann; Jörg Mages; Roland Lang; Sylvie Robine; Martin F Kagnoff; Roland M Schmid; Michael Karin; Melek C Arkan; Florian R Greten
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-24       Impact factor: 11.205

Review 6.  Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword.

Authors:  Elke Cario
Journal:  Inflamm Bowel Dis       Date:  2008-03       Impact factor: 5.325

7.  Epithelial NEMO links innate immunity to chronic intestinal inflammation.

Authors:  Arianna Nenci; Christoph Becker; Andy Wullaert; Ralph Gareus; Geert van Loo; Silvio Danese; Marion Huth; Alexei Nikolaev; Clemens Neufert; Blair Madison; Deborah Gumucio; Markus F Neurath; Manolis Pasparakis
Journal:  Nature       Date:  2007-03-14       Impact factor: 49.962

8.  Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88.

Authors:  Seth Rakoff-Nahoum; Ruslan Medzhitov
Journal:  Science       Date:  2007-07-06       Impact factor: 47.728

9.  Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis.

Authors:  Tomohiro Watanabe; Naoki Asano; Peter J Murray; Keiko Ozato; Prafullakumar Tailor; Ivan J Fuss; Atsushi Kitani; Warren Strober
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

10.  Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis.

Authors:  Marika C Kullberg; Dragana Jankovic; Peter L Gorelick; Patricia Caspar; John J Letterio; Allen W Cheever; Alan Sher
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  55 in total

Review 1.  Expression and functional importance of innate immune receptors by intestinal epithelial cells.

Authors:  Rute Marques; Ivo G Boneca
Journal:  Cell Mol Life Sci       Date:  2011-10-08       Impact factor: 9.261

2.  TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface.

Authors:  John Sotolongo; Saravana Kanagavelu; Jinhee Hyun; Jose Ruiz; Masayuki Fukata
Journal:  Gut Microbes       Date:  2012-06-20

3.  MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands.

Authors:  Katharina Brandl; Lei Sun; Christina Neppl; Owen M Siggs; Sylvain M Le Gall; Wataru Tomisato; Xiaohong Li; Xin Du; Daniela N Maennel; Carl P Blobel; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

4.  Intestinal epithelium-specific MyD88 signaling impacts host susceptibility to infectious colitis by promoting protective goblet cell and antimicrobial responses.

Authors:  Ganive Bhinder; Martin Stahl; Ho Pan Sham; Shauna M Crowley; Vijay Morampudi; Udit Dalwadi; Caixia Ma; Kevan Jacobson; Bruce A Vallance
Journal:  Infect Immun       Date:  2014-06-23       Impact factor: 3.441

Review 5.  Unravelling the effects of the environment and host genotype on the gut microbiome.

Authors:  Aymé Spor; Omry Koren; Ruth Ley
Journal:  Nat Rev Microbiol       Date:  2011-04       Impact factor: 60.633

Review 6.  Pharmacological intervention studies using mouse models of the inflammatory bowel diseases: translating preclinical data into new drug therapies.

Authors:  Iurii Koboziev; Fridrik Karlsson; Songlin Zhang; Matthew B Grisham
Journal:  Inflamm Bowel Dis       Date:  2011-02-10       Impact factor: 5.325

7.  Lysozyme promotes the release of Toll-like receptor-2 stimulants from gram-positive but not gram-negative intestinal bacteria.

Authors:  Clett Erridge
Journal:  Gut Microbes       Date:  2010 Nov-Dec

8.  Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa.

Authors:  Aline Dupont; Lena Heinbockel; Klaus Brandenburg; Mathias W Hornef
Journal:  Gut Microbes       Date:  2014

Review 9.  Immunogenetic control of the intestinal microbiota.

Authors:  Eric Marietta; Abdul Rishi; Veena Taneja
Journal:  Immunology       Date:  2015-06-03       Impact factor: 7.397

Review 10.  Deciphering interactions between the gut microbiota and the immune system via microbial cultivation and minimal microbiomes.

Authors:  Thomas Clavel; João Carlos Gomes-Neto; Ilias Lagkouvardos; Amanda E Ramer-Tait
Journal:  Immunol Rev       Date:  2017-09       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.